Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...

We recently published a list of 10 Best Retirement Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Merck (NYSE:MRK) shares snaps six straight sessions of gains, as the stock closed 2.2% lower at $89.38 on Wednesday.

Drugmaker Merck , known as MSD outside of the U.S. and Canada, expects to increase its workforce across its India sites by ...

Merck (NYSE:MRK) shares were on track to snap six straight sessions of gains on Wednesday, as the stock fell 2.8% at $88.87 ...

A higher prostate cancer behavior score was associated with a 31% reduction in the hazard for all-cause mortality and a 33% ...

Cancer vaccines harness the power of the immune system to stop tumors in their tracks. They work a little differently than ...

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more ...

Merck & Co. and Glenmark Pharmaceuticals Ltd. failed to convince a federal judge to toss antitrust claims tied to an alleged ...

Records show that drug companies gave nearly $75,000 to the top Republican and Democrat on a committee investigating them.

A panel of scientific experts that advises the Food and Drug Administration on vaccine policy learned Wednesday that its upcoming meeting to discuss next year’s flu vaccines had been canceled.